Mural Oncology plc financial data

Location
Dublin 2, Ireland
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 469% % -49%
Debt-to-equity 26% % 78%
Return On Equity -131% % -88%
Return On Assets -105% % -71%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17,344,486 shares 1.7%
Common Stock, Shares, Outstanding 17,324,771 shares 1.7%
Entity Public Float $32,178,017 USD
Common Stock, Value, Issued $174,000 USD 2.4%
Weighted Average Number of Shares Outstanding, Basic 17,321,544 shares 1.7%
Weighted Average Number of Shares Outstanding, Diluted 17,321,544 shares 1.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $106,956,000 USD -22%
General and Administrative Expense $30,477,000 USD -17%
Operating Income (Loss) $123,046,000 USD 24%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $119,099,000 USD 23%
Earnings Per Share, Basic -6 USD/shares 24%
Earnings Per Share, Diluted -6 USD/shares 24%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $58,871,000 USD -47%
Other Assets, Current $364,000 USD -52%
Assets, Current $62,158,000 USD -66%
Property, Plant and Equipment, Net $466,000 USD -95%
Operating Lease, Right-of-Use Asset $3,134,000 USD -64%
Other Assets, Noncurrent $3,000 USD -96%
Assets $65,758,000 USD -68%
Accounts Payable, Current $3,142,000 USD 1.1%
Employee-related Liabilities, Current $4,292,000 USD -21%
Accrued Liabilities, Current $6,790,000 USD -61%
Liabilities, Current $10,530,000 USD -58%
Operating Lease, Liability, Noncurrent $42,000 USD -99%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $10,572,000 USD -64%
Retained Earnings (Accumulated Deficit) $244,196,000 USD -95%
Stockholders' Equity Attributable to Parent $55,186,000 USD -68%
Liabilities and Equity $65,758,000 USD -68%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $36,798,000 USD 1.4%
Net Cash Provided by (Used in) Financing Activities $28,000,000 USD
Net Cash Provided by (Used in) Investing Activities $27,990,000 USD
Common Stock, Shares Authorized 450,000,000 shares 0%
Common Stock, Shares, Issued 17,324,771 shares 1.7%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $8,780,000 USD 95%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60,582,000 USD -46%
Deferred Tax Assets, Valuation Allowance $50,696,000 USD 755%
Operating Lease, Liability $3,547,000 USD -63%
Depreciation $3,617,000 USD 14%
Payments to Acquire Property, Plant, and Equipment $10,000 USD -82%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $119,146,000 USD 22%
Lessee, Operating Lease, Liability, to be Paid $3,600,000 USD -64%
Property, Plant and Equipment, Gross $32,802,000 USD -27%
Operating Lease, Liability, Current $3,505,000 USD -36%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,484,000 USD -63%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,484,000 USD -63%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $53,000 USD -83%
Deferred Tax Assets, Operating Loss Carryforwards $8,206,000 USD 1049%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $299,208,000 USD 0.06%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $2,167,000 USD -35%
Share-based Payment Arrangement, Expense $163,000 USD -99%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%